SCHEMBL6504642

SCHEMBL6504642

CCC(C)(C)CCC(Nc1nc(=O)n(C)c2ccccc12)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 4/20 0.34
TDP1 Q9NUW8 2/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
MAPT P10636 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6504632 1.00 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL6493915 0.84 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL6348481 0.84 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL6505115 0.82 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL6505120 0.82 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL4834842 0.78 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL6498155 0.78 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL4828733 0.69 ALDH1A1 (0.34) ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL31052849 0.68 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1NPSR1LMNA
SCHEMBL4828758 0.68 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US claimed
EP-1434769-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-07-07 EP claimed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US claimed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 WO claimed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB ALDH1A1 2191/4885KMT2A 4544/4885MEN1 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.